Latest news
Tissue-Agnostic Medicine Has a New Proof Point
The FDA has converted selpercatinib to traditional approval for RET fusion-positive solid tumours in adults and children. The decision strengthens tissue-agnostic precision oncology, but testing gaps still decide who is found.
IPM Brief – Issue 2 | The Gatekeepers Are Moving
GIST Care Looks Beyond First-Generation KIT Control
Pancreatic Cancer Finally Gets a RAS Moment
A Rare Pain Disorder Gets a Pivotal Trial
Soft-Cheese Listeria Outbreak Shows Food Safety Is Patient Safety
World Cup Health Guidance Turns Football Into a Public-Health Test
Not All Eye Infections Are Equal: New Evidence Points to a Precision Medicine Approach
What happens when surgeons no longer need to be in the same country as their patients?
EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.